- Home
- ALNY vs ABEV Comparison
ALNY vs ABEV Comparison
Compare ALNY & ABEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | ABEV |
|---|---|---|
| Founded | 2002 | 1885 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 43.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALNY | ABEV |
|---|---|---|
| Price | $322.95 | $3.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 27 | 4 |
| Target Price | ★ $474.42 | $2.53 |
| AVG Volume (30 Days) | 1.6M | ★ 26.4M |
| Earning Date | 02-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 6.40% |
| EPS Growth | N/A | ★ 15.78 |
| EPS | ★ 0.33 | 0.19 |
| Revenue | $3,210,070,000.00 | ★ $16,975,691,794.00 |
| Revenue This Year | $70.40 | $3.57 |
| Revenue Next Year | $44.32 | $4.38 |
| P/E Ratio | $979.16 | ★ $15.67 |
| Revenue Growth | ★ 53.24 | 9.79 |
| 52 Week Low | $205.87 | $1.83 |
| 52 Week High | $495.55 | $3.03 |
Technical Indicators
Market Signals| Indicator | ALNY | ABEV |
|---|---|---|
| Relative Strength Index (RSI) | 29.08 | 82.80 |
| Support Level | $333.00 | $2.88 |
| Resistance Level | $355.49 | $2.87 |
| Average True Range (ATR) | 11.22 | 0.06 |
| MACD | -1.16 | 0.02 |
| Stochastic Oscillator | 8.92 | 95.71 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About ABEV Ambev S.A.
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.